arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Nurix Therapeutics, Inc.

NRIX

$23.88 ▼ -1.80 (-7.03%) at close

8 Visible periods

28 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Nurix Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $2.1B

Dividend Yield —

Revenue Growth 54.0% ↗

Op. Margin -340.2% ↗

ROIC -53.2% ↘

FCF / Share $-3.04 ↘

Trailing P/E —

Price / Book 4.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$83.98M

↑ +54.0% —

Net Income Profit after all expenses

$-264.46M

↓ -36.6% —

Operating Margin Operating profit as % of sales

-340.2%

↑ +12.9% 0th

FCF / Share Free cash flow per share

$-3.04

↓ -12.2% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Operating Margin (%)Operating Margin (%) is in the bottom quartile
Profit Margin (%)Profit Margin (%) is in the bottom quartile
Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑

Returns ↓

Cash Quality ↑

Dividend History

Dividend / share · sourced from SEC filings

$0.00 Latest / share

FY 2018

$0.00

FY 2019

$0.00

FY 2020

FY 2021

FY 2022

FY 2023

$0.00

FY 2024

$0.00

FY 2025

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Nov 30, 2025 10-K ↗	FY 2024 Nov 30, 2024 10-K ↗	FY 2023 Nov 30, 2023 10-K ↗	FY 2022 Nov 30, 2022 10-K ↗	FY 2021 Nov 30, 2021 10-K ↗	FY 2020 Nov 30, 2020 10-K ↗	FY 2019 Nov 30, 2019 10-K ↗	FY 2018 Nov 30, 2018 10-K ↗
Revenue Growth YoY (%)	54.0% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+574%)	-29.1% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-464%)	99.3% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+1141%)	29.8% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+273%)	66.9% Excellent Excellent Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+737%)	-42.7% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-634%)	—	—
EPS Growth YoY (%)	-5.9% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	-8.7% Weak ↓ Weak Declining Year-over-year change in earnings per share Optimal: > 10%	28.6% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	-35.9% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	-36.6% Weak ↓ Weak Declining Year-over-year change in net income	-34.5% Weak ↑ Weak Improving Year-over-year change in net income	20.2% Good ↑ Good Improving Year-over-year change in net income	-53.9% Weak ↑ Weak Improving Year-over-year change in net income	-171.0% Weak Weak Year-over-year change in net income	-99.3% Weak Weak Year-over-year change in net income	—	—
FCF Growth YoY (%)	-12.2% Weak ↑ Weak Improving Year-over-year change in free cash flow	-64.0% Weak ↓ Weak Declining Year-over-year change in free cash flow	53.3% Excellent Excellent Year-over-year change in free cash flow	-68.7% Weak Weak Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	29.5% Excellent → Excellent Stable Compound annual revenue growth over 3 years	22.4% Excellent ↓ Excellent Declining Compound annual revenue growth over 3 years	62.9% Excellent Excellent Compound annual revenue growth over 3 years	7.5% Fair Fair Compound annual revenue growth over 3 years	—	—	—	—
Revenue CAGR 5Y (%)	36.3% Excellent Excellent Compound annual revenue growth over 5 years	11.9% Good Good Compound annual revenue growth over 5 years	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	FY 2025 Nov 30, 2025 10-K ↗	FY 2024 Nov 30, 2024 10-K ↗	FY 2023 Nov 30, 2023 10-K ↗	FY 2022 Nov 30, 2022 10-K ↗	FY 2021 Nov 30, 2021 10-K ↗	FY 2020 Nov 30, 2020 10-K ↗	FY 2019 Nov 30, 2019 10-K ↗	FY 2018 Nov 30, 2018 10-K ↗
Operating Margin (%) (%)	-340.2% Weak → Weak Stable Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2368%)	-390.5% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2703%)	-201.4% Weak ↑ Weak Improving Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1443%)	-476.0% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3273%)	-396.3% Weak ↓ Weak Declining Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2742%)	-364.7% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2531%)	-71.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-576%)	—
Effective Tax Rate (%) (%)	-0.3% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	32.2% Weak Weak Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.1% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—
Profit Margin (%) (%)	-314.9% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2724%)	-354.9% Weak → Weak Stable Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3057%)	-187.0% Weak ↑ Weak Improving Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1658%)	-466.9% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3991%)	-393.9% Weak ↓ Weak Declining Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-3383%)	-242.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2122%)	-69.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-681%)	—
FCF Margin (%) (%)	-313.7% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-333.4% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-116.6% Weak ↑ Weak Improving Free cash flow as a percentage of revenue Optimal: > 10%	-445.4% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-302.6% Weak ↓ Weak Declining Free cash flow as a percentage of revenue Optimal: > 10%	-26.0% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	-3.4% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—
FCF / Net Income (x)	1.00x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.94x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.62x Weak → Weak Stable Free cash flow relative to reported net income Optimal: > 1x	0.95x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.77x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.11x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	0.05x Weak Weak Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Nov 30, 2025 10-K ↗	FY 2024 Nov 30, 2024 10-K ↗	FY 2023 Nov 30, 2023 10-K ↗	FY 2022 Nov 30, 2022 10-K ↗	FY 2021 Nov 30, 2021 10-K ↗	FY 2020 Nov 30, 2020 10-K ↗	FY 2019 Nov 30, 2019 10-K ↗	FY 2018 Nov 30, 2018 10-K ↗
Return on Invested Capital (%)	-53.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-40.5% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-77.3% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-60.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-34.5% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-15.2% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	39.0% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-41.5% Weak → Weak Stable Operating profit relative to total assets Optimal: > 10%	-31.8% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-43.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-44.1% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-24.7% Weak ↑ Weak Improving Operating profit relative to total assets Optimal: > 10%	-16.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	-50.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-49.1% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-427%)	-36.7% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-345%)	-71.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-579%)	-59.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-496%)	-34.2% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-328%)	-14.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-199%)	37.6% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+151%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Nov 30, 2025 10-K ↗	FY 2024 Nov 30, 2024 10-K ↗	FY 2023 Nov 30, 2023 10-K ↗	FY 2022 Nov 30, 2022 10-K ↗	FY 2021 Nov 30, 2021 10-K ↗	FY 2020 Nov 30, 2020 10-K ↗	FY 2019 Nov 30, 2019 10-K ↗	FY 2018 Nov 30, 2018 10-K ↗
Net Debt (USD)	$-246.96M	$-110.00M	$-54.63M	$-64.47M	$-80.51M	$-119.36M	$-34.82M	—

📊 What does each share earn? 8 metrics

Metric	FY 2025 Nov 30, 2025 10-K ↗	FY 2024 Nov 30, 2024 10-K ↗	FY 2023 Nov 30, 2023 10-K ↗	FY 2022 Nov 30, 2022 10-K ↗	FY 2021 Nov 30, 2021 10-K ↗	FY 2020 Nov 30, 2020 10-K ↗	FY 2019 Nov 30, 2019 10-K ↗	FY 2018 Nov 30, 2018 10-K ↗
Revenue per Share (USD)	$0.97	$0.81	$1.42	$0.79	$0.69	—	—	—
Basic EPS, GAAP (USD)	$-3.05	$-2.88	$-2.65	$-3.71	$-2.73	—	—	—
Free Cash Flow per Share (USD)	$-3.04	$-2.71	$-1.65	$-3.54	$-2.10	—	—	—
Dividend per Share (USD)	$0.00	$0.00	—	—	—	$0.00	$0.00	—
Book Value per Share (USD)	$5.29	$6.95	$4.12	$6.44	$7.66	$7.47	$-16.05	—
Tangible Book Value per Share (USD)	$5.29	$6.95	$4.12	$6.44	$7.66	$7.47	$-16.05	—
Basic Weighted Avg Shares (shares)	86.67M	67.12M	54.34M	48.61M	42.90M	—	—	—
Dividend Payout Ratio (%)	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	0.0% Excellent Excellent Dividends paid as a percentage of earnings Optimal: 30-60%	—	—	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Nov 30, 2025 10-K ↗	FY 2024 Nov 30, 2024 10-K ↗	FY 2023 Nov 30, 2023 10-K ↗	FY 2022 Nov 30, 2022 10-K ↗	FY 2021 Nov 30, 2021 10-K ↗	FY 2020 Nov 30, 2020 10-K ↗	FY 2019 Nov 30, 2019 10-K ↗	FY 2018 Nov 30, 2018 10-K ↗
Working Capital (USD)	$520.35M	$523.53M	$208.54M	$247.79M	$244.86M	$253.90M	$23.22M	—
Total Equity (USD)	$538.75M	$526.99M	$200.49M	$303.70M	$342.30M	$290.27M	$-57.71M	$-36.85M

📋 What is driving earnings? 3 metrics

Metric	FY 2025 Nov 30, 2025 10-K ↗	FY 2024 Nov 30, 2024 10-K ↗	FY 2023 Nov 30, 2023 10-K ↗	FY 2022 Nov 30, 2022 10-K ↗	FY 2021 Nov 30, 2021 10-K ↗	FY 2020 Nov 30, 2020 10-K ↗	FY 2019 Nov 30, 2019 10-K ↗	FY 2018 Nov 30, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$83.98M	$54.55M	$76.99M	$38.63M	$29.75M	$17.82M	$31.11M	—
Net Income, GAAP (USD)	$-264.46M	$-193.57M	$-143.95M	$-180.36M	$-117.19M	$-43.24M	$-21.70M	—
Operating Cash Flow (USD)	$-249.47M	$-172.58M	$-81.36M	$-159.81M	$-84.36M	$-80.00K	$601.00K	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 31 quarters

Nurix Therapeutics, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Dividend History

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare NRIX with peers